BioLamina Secures €20M EIB Loan to Enhance Cell Therapy Technologies
BioLamina, a Stockholm-based biotechnology company, has secured a €20 million loan from the European Investment Bank (EIB) to expand its production of laminin technologies. These technologies are crucial for developing next-generation cell therapies and animal-free drug safety testing methods. BioLamina produces protein scaffolding used to grow stem cells for therapeutic applications, providing extracellular matrix proteins that allow researchers to grow, expand, and differentiate stem cells outside the body. The funding will support the development of laminin technologies that enable more consistent and clinically compliant cell products, with potential applications in treating various diseases.